Purnanand D. Sarma
Equibles does not estimate personal net worth.
About Purnanand D. Sarma
Purnanand D. Sarma was last confirmed as CEO at Immunome Inc. (IMNM) in a filing dated April 20, 2023. Earlier roles on record: Board Member at Immunome Inc. (IMNM) until October 2, 2023. Immunome Inc. reported in an 8-K filed October 4, 2023 that Purnanand D. Sarma resigned as Immunome's board of directors and any respective committee membership of Immunome's board of directors, effective October 2, 2023. The same filing states: “The resignation of each of the above referenced directors was not the result of a disagreement with Immunome on any matter relating to its operations, policies or practices.” Immunome Inc. reported in an 8-K filed October 4, 2023 that Purnanand D. Sarma resigned as officer and employee of Immunome, effective October 2, 2023. The same filing states: “The resignation of each of the above referenced directors was not the result of a disagreement with Immunome on any matter relating to its operations, policies or practices.” The proxy statement of Immunome Inc. reports total compensation of $1,437,295 for Purnanand D. Sarma in fiscal 2023, including a base salary of $440,820. Disclosed compensation is on record for 5 fiscal years.
“(ii) Purnanand D. Sarma, Ph.D. resigned from Immunome's board of directors and any respective committee membership of Immunome's board of directors, and resigned as an officer and employee of Immunome for Good Reason under the terms of his Amended and Restated Employment Agreement with Immunome, dated October 14, 2020, in each case, effective as of the closing of the Merger”
“The resignation of each of the above referenced directors was not the result of a disagreement with Immunome on any matter relating to its operations, policies or practices.”
“(ii) Purnanand D. Sarma, Ph.D. resigned from Immunome's board of directors and any respective committee membership of Immunome's board of directors, and resigned as an officer and employee of Immunome for Good Reason under the terms of his Amended and Restated Employment Agreement with Immunome, dated October 14, 2020, in each case, effective as of the closing of the Merger”
“The resignation of each of the above referenced directors was not the result of a disagreement with Immunome on any matter relating to its operations, policies or practices.”
Affiliation history
-
2019-01-01–2023-10-02
-
Start not stated–2023-04-20
Last confirmed by a filing; no departure on record
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Immunome Inc. (IMNM) | Former Chief Executive Officer | $440,820 | $1,437,295 |
| 2022 | Immunome Inc. (IMNM) | Former Chief Executive Officer | $540,000 | $990,309 |
| 2021 | Immunome Inc. (IMNM) | President, Chief Executive Officer and Director | $540,000 | $2,111,914 |
| 2020 | Immunome Inc. (IMNM) | President, Chief Executive Officer and Director | $435,000 | $1,695,002 |
| 2019 | Immunome Inc. (IMNM) | President, Chief Executive Officer and Director | $233,333 | $339,910 |
Recent activity
-
Executive change Resigned: Immunome's board of directors and any respective committee membership of Immunome's board of directors
“The resignation of each of the above referenced directors was not the result of a disagreement with Immunome on any matter relating to its operations, policies or practices.”
Immunome Inc. (IMNM) -
Executive change Resigned: officer and employee of Immunome
“The resignation of each of the above referenced directors was not the result of a disagreement with Immunome on any matter relating to its operations, policies or practices.”
Immunome Inc. (IMNM)